Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Twelve months ago, the treasury team at Gilead Sciences, Inc., a fast-growing biopharmaceutical business that develops and produces treatments for some of the world’s deadliest diseases, faced some critical challenges. The company brings in close to $10 billion in annual revenue through operations in more than 30 countries. Yet its small treasury staff was spending more time on transaction processing than on analysis, and manual data entry put the company at risk for errors.

Treasury & Risk

Don’t miss crucial treasury and finance news along with in-depth analysis and insights you need to make informed treasury decisions. Join Treasury & Risk now!

  • Free unlimited access to Treasury & Risk including case studies with corporate innovators, informative newsletters, educational webcasts, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM publications including PropertyCasualty360.com and Law.com.

Already have an account? Sign In Now

Copyright © 2018 ALM Media Properties, LLC. All Rights Reserved.